Global Epilepsy Drugs Market 2018-2022 with Eisai, GlaxoSmithKline, Novartis & Pfizer Dominating - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 2, 2018--The “Global Epilepsy Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The Global Epilepsy Drugs Market to grow at a CAGR of 7.19% during the period 2018-2022.
Global Epilepsy Drugs Market 2018-2022 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver influencing this market is the advances in understanding of epilepsy pathology. Several programs have been launched worldwide to develop effective and safe drugs for the treatment of seizures in epileptic patients which is expected to boost the growth of the epilepsy drugs market in the next few years.
One trend affecting this market is the increasing costs of epilepsy management. The direct costs associated with the treatment of epilepsy include costs of hospitalization, outpatient treatment, diagnostic workup, nursing care, and parents’ copayments is increasing.
Further, the report states that one challenge affecting this market is the low safety profile of AEDs. The global epilepsy drugs market has several clinical and non-clinical unmet needs, such as low safety profile of AEDs especially among women.
Key vendors:Eisai GlaxoSmithKline Novartis Pfizer
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSISUnmet needs of available AEDs Pipeline drugs for epilepsy
PART 06: MARKET SIZING
PART 07: MARKET SIZING 2017-2022
PART 08: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 09: MARKET SEGMENTATION BY DRUG ACTIVITY SPECTRUMSegmentation by drug activity spectrum Comparison by drug activity spectrum Narrow spectrum drugs Broad spectrum drugs Market opportunity by drug activity spectrum
PART 10: MARKET SEGMENTATION BY ETIOLOGYSegmentation by etiology
PART 11: MARKET SEGMENTATION BY AGE OF ONSET
PART 12: CUSTOMER LANDSCAPE
PART 13: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Market opportunity
PART 14: DECISION FRAMEWORK
PART 15: DRIVERS AND CHALLENGES
PART 16: MARKET TRENDSIncrease in epilepsy management costs Use of immunotherapy and immunomodulators Use of genetics as therapeutics and diagnostic modality Research in precision healthcare infrastructure
PART 17: VENDOR LANDSCAPELandscape disruption
PART 18: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/h8gbh2/global_epilepsy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005865/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/02/2018 12:33 PM/DISC: 10/02/2018 12:33 PM